RESPIRATORY SYNCYTIAL VIRUS INFECTION
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTION explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTION trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New RSV vaccine shows promise in protecting seniors from severe lung disease
⭐️ VACCINE ⭐️ CompletedThis study tested an experimental RSV vaccine in about 4500 adults aged 60 and older. Half received the vaccine and half received a placebo. The goal was to see if the vaccine could prevent lower respiratory tract disease caused by RSV, a common virus that can be dangerous for ol…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 06:51 UTC
-
One shot, three viruses: new vaccine trial for seniors
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested a new vaccine that aims to protect against three respiratory viruses at once: RSV, hMPV, and PIV3. About 390 adults aged 60 and older received different combinations of the vaccine to check safety and whether it helps the body make protective antibod…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 06:49 UTC
-
New combo vaccine targets two winter viruses in seniors
⭐️ VACCINE ⭐️ CompletedThis study tested a single-shot vaccine designed to protect against two respiratory viruses—RSV and hMPV—in adults aged 60 and older. Researchers gave different doses to 646 volunteers and checked for side effects and immune responses. A booster shot was also tested 12 months lat…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:57 UTC
-
New mRNA vaccine aims to fight two respiratory viruses at once
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested an experimental mRNA vaccine designed to protect against two respiratory viruses: RSV and hMPV. Healthy adults aged 18-49 and 60+ received a single shot at different doses. Researchers monitored safety and immune responses for about 6 months.
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 12, 2026 13:41 UTC
-
New RSV vaccine shows promise in young children
⭐️ VACCINE ⭐️ CompletedThis study tested a weakened live RSV vaccine in 259 infants and toddlers aged 6 to 18 months. The goal was to check the vaccine's safety and how well it triggers an immune response. Researchers measured side effects and antibody levels to find the best dose.
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 07, 2026 18:41 UTC
-
New RSV vaccine trial in puerto rico aims to protect little lungs
⭐️ VACCINE ⭐️ CompletedThis study tested a live, weakened RSV vaccine in healthy infants and toddlers aged 6 to 24 months in Puerto Rico. The main goal was to see if the vaccine virus spreads to others in the home or daycare, how much virus is shed, and if it stays genetically stable. Researchers also …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 29, 2026 15:01 UTC
-
Breakthrough RSV shot shields thousands of babies from severe lung infections
Prevention CompletedThis large study tested a single dose of clesrovimab in over 3,600 healthy preterm and full-term infants to see if it could prevent serious RSV lung infections. The medicine was given before or during RSV season and compared to a placebo. Results showed fewer babies getting sick …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated May 17, 2026 07:04 UTC